The most common question we field about HPV vaccination from adult patients is some version of: I'm 34 — am I too old? The answer that "the vaccine is licensed up to 26" used to be technically accurate and clinically unhelpful. In the last five years, both the regulatory framing and the clinical evidence have shifted. The current consensus is more nuanced and, for many adults, more permissive than the old cutoff implied.
This article walks through what changed, who actually benefits from catch-up vaccination, what the schedule looks like, and what to expect at the clinic.
Considering the vaccine? We run adult HPV vaccination in Makati — see what is involved and how to book.
What does the HPV vaccine actually prevent?
The vaccine in use globally is Gardasil 9 (9-valent recombinant HPV vaccine), which covers nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Between them, those nine types are responsible for roughly:
- ~90% of genital warts (mostly types 6 and 11)
- ~90% of cervical cancers
- ~90% of anal cancers
- ~60–70% of oropharyngeal cancers
- The majority of HPV-associated penile and vulvovaginal cancers1
The vaccine is prophylactic, not therapeutic. It does not treat an existing HPV infection. But because HPV is a family of more than 200 viruses and only a handful infect a given person over a lifetime, vaccination at any age still offers prospective protection against types not yet acquired.
Why isn't the HPV vaccine recommended after 26?
The original licensure trials for HPV vaccines enrolled women up to age 26 and men up to age 21–26, primarily because the assumed public-health value was highest in young people not yet sexually active. The "26" number embedded itself in regulatory language for years afterward.
In 2018–2019, the FDA expanded the approved age range up to 45 for both men and women, based on a Phase III trial in women aged 24–45 that showed strong efficacy in HPV-naive participants and reasonable immunogenicity overall.2 The CDC and ACIP followed in 2019 with a "shared clinical decision-making" recommendation for adults aged 27 through 45 — language meaning not routinely recommended for everyone, but appropriate to discuss and individualise.3
That phrase — shared clinical decision-making — is the part patients usually need explained. It does not mean the vaccine is unavailable or ineffective for adults past 26. It means the benefit varies by individual circumstances, and the appropriate venue for that conversation is a clinical consultation rather than a population-wide mandate.
For most adults aged 27–45, HPV vaccination is no longer "indicated for everyone" but is a reasonable, often beneficial individual choice. The clearest gains are for adults with low prior exposure, a new partner, an upcoming change in relationship status, or any specific risk factor. Adults beyond 45 derive smaller absolute benefits but are not categorically excluded.
Who benefits most from getting it after 26?
The single best predictor of vaccine value is how many of the nine vaccine-covered HPV types the patient has already encountered. The fewer prior exposures, the larger the prospective benefit. In practice this maps onto a handful of patient profiles where we routinely recommend catch-up:
- Adults with limited prior sexual exposure. Self-explanatory: the vaccine prevents what hasn't happened yet.
- Adults entering a new relationship or beginning to date again (after divorce, bereavement, a long single period). The change in exposure pattern resets some of the calculus.
- Men and women with a current diagnosis of genital warts (low-risk HPV). The likelihood of having all nine vaccine-covered types is small; vaccination still covers the high-risk strains.
- Men who have sex with men. Higher rates of anal HPV and HPV-associated anal cancer make the absolute benefit meaningfully larger.
- People living with HIV or other immunosuppression. Reduced clearance of HPV makes the protective window narrower and the prospective benefit larger.
- Anyone with a partner being treated for HPV-related disease. Reciprocal protection is reasonable.
For adults who don't fit any of the above — long-monogamous, no current symptoms, no expected change in exposure pattern — the absolute benefit is smaller, but the safety record is excellent and the conversation is still worth having.
Can men get the HPV vaccine after 26?
Yes — and the question comes up constantly, usually from men who were told at some point that HPV vaccination is a women's issue. It is licensed for men and women alike, and in the Philippines it is available to adults up to 45 on the same shared-decision basis.
The reason it matters for men is not politeness toward a partner. HPV causes anal, penile and oropharyngeal cancers, and it causes genital warts. There is no routine HPV screening test for men equivalent to cervical screening in women — no smear, no recall letter. Prevention is the only lever available.
That asymmetry is the whole argument: a woman who skips vaccination still gets screened. A man who skips it gets nothing.
Does the HPV vaccine still work after 26?
Vaccine immunogenicity (the antibody response generated) remains strong well into adulthood — somewhat lower than in adolescents but in the same protective range. Vaccine efficacy in HPV-naive adults in the 24–45 age range was 88% against persistent infection and HPV-related disease for the covered types in pivotal trials.2
The decline in benefit at older ages is not because the vaccine "stops working" — it is because cumulative prior exposure means a larger share of any individual's prevention budget has already been spent. Two adults of the same age can have very different vaccination value depending on their history.
How many doses do adults need?
| Age at first dose | Number of doses | Schedule |
|---|---|---|
| 9–14 years | 2 doses | 0 and 6–12 months |
| 15 and older | 3 doses | 0, 1–2, and 6 months |
| Immunocompromised (any age) | 3 doses | 0, 1–2, and 6 months |
Adults starting catch-up vaccination get the 3-dose schedule. The full course is completed in about 6 months. Missing the exact dosing window by a few weeks doesn't restart the series — the doses simply resume from where they were paused.
Is the HPV vaccine safe for adults?
Gardasil 9 is one of the most extensively monitored vaccines in modern use. Across hundreds of millions of doses administered globally:
- Common, expected side effects: injection-site soreness, redness, swelling; transient fatigue; occasional low-grade fever or headache. Most resolve within 24–48 hours.
- Syncope (fainting) is occasionally seen, particularly in adolescents and young adults; this is why patients are typically observed for 15 minutes after the dose, seated.
- Serious adverse events are rare and not consistently shown to be causally linked to the vaccine in the large post-marketing surveillance databases.4
The vaccine is contraindicated in patients with a documented severe allergic reaction to a previous dose or to a vaccine component. It is generally avoided during pregnancy — if you become pregnant mid-series, you simply complete the remaining doses postpartum.
If you are a woman weighing this up: we have a section covering cervical cancer risk in the Philippines, why the vaccine does not replace screening, and whether it is still worth it after an abnormal smear — HPV vaccination for women.
If you manage a team: employer-sponsored HPV programmes reach the adult women no public programme covers. Details on corporate HPV vaccination.
Is the HPV vaccine covered by PhilHealth?
Not for adults, as things stand. PhilHealth does not currently reimburse adult HPV vaccination as an outpatient benefit. The free HPV vaccine you may have read about is the Department of Health's school-based programme, which covers Grade 4 girls in public elementary schools — it is not a PhilHealth claim and it does not extend to adults.
A bill extending free national immunisation to adults has been filed but is not in force. Because this is exactly the kind of thing that changes, confirm the current position with PhilHealth directly rather than relying on any clinic's website — including this one.
In practice, adult HPV vaccination in the Philippines is paid out of pocket at private clinics.
How much does the HPV vaccine cost in the Philippines?
Gardasil 9 runs roughly ₱6,000–₱8,000 per dose across private clinics and hospitals in Metro Manila, which puts a three-dose adult course at somewhere between ₱18,000 and ₱24,000. Advocacy-priced providers sit at the bottom of that band; private hospitals sit at the top.
At our clinic it is ₱7,200 per dose, ₱21,000 for the full three-dose course, or ₱20,400 if you settle the course in advance. Every one of those is all-in — vaccine, administration and the 15-minute observation. There is no separate injection fee and no consultation fee added on top.
That last point is the one worth carrying into any comparison you make. Many clinics and hospitals quote you the vial and then add ₱500–₱1,500 per visit for administration. Across three visits that is ₱1,500–₱4,500 nobody mentioned at the counter, and it is why two quotes that look ₱1,000 apart can finish ₱3,000 apart. Ask the question directly: does that price include giving it to me?
We are not the cheapest option in Metro Manila and there is no point pretending otherwise — if price is your only criterion, the advocacy clinics are worth a call. What we publish is a number that does not move between the enquiry and the invoice.
For adults in their late 20s through 40s, the most useful framing is: this is a once-in-a-lifetime, six-month course of three injections. The protection is long — current data suggest at least 10–15 years and likely lifelong for the covered types — and the safety record is excellent.
The one thing patients underestimate
The cancers HPV causes are not a future risk in the abstract. HPV-related oropharyngeal cancer in men, in particular, has been rising over the past two decades and now exceeds cervical cancer rates in many high-income countries.5 The vaccine isn't only about women's cancer prevention. The cleanest single-sentence case for adult HPV vaccination is one that men often haven't heard: you are protecting yourself, not someone else.
If you have ever been told "you're too old for HPV vaccine," it is worth a 15-minute consultation to revisit. The answer may still be no — but for many adults in their thirties and forties, the answer is actually yes, with a clearer rationale than they were given the first time.
Related reading: The HPV vaccine for men in the Philippines · HPV and genital warts · Adult vaccinations at the clinic.